ERBB4 over exp
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ERBB4
Variant over exp
Impact List none
Protein Effect no effect
Gene Variant Descriptions ERBB4 over exp indicates an over expression of the Erbb4 protein. However, the mechanism causing the over expression is unspecified.
Associated Drug Resistance
Category Variants Paths

ERBB4 over exp

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB4 over exp marginal zone lymphoma resistant Idelalisib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line was found to have ERBB4 overexpression following acquired resistance to Zydelig (idealisib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Umbralisib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Ukoniq (umbralisib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Duvelisib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Copiktra (duvelisib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Copanlisib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Aliqopa (copanlisib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Ibrutinib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Zanubrutinib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Brukinsa (zanubrutinib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Acalabrutinib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Calquence (acalabrutinib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Pirtobrutinib Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to Jaypirca (pirtobrutinib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma resistant Idelalisib + Rituximab Preclinical - Cell culture Actionable In a preclinical study, a marginal zone lymphoma cell line with ERBB4 overexpression demonstrated resistance to combination treatment with Rituxan (rituximab) and Zydelig (idelalisib) in culture (PMID: 38052765). 38052765
ERBB4 over exp marginal zone lymphoma sensitive Idelalisib + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, the addition of Tykerb (lapatinib) restored sensitivity to Zydelig (idealisib) and led to synergistic inhibition of viability in a marginal zone lymphoma cell line with ERBB4 overexpression in culture (PMID: 38052765). 38052765